To evaluate the effects of vinpocetine on dizziness and brain-derived neurotrophic factor (BDNF) plasma level in patients with cerebrovascular disease.
Material and methods
In the open-label 12-week clinical study 120 patients with cerebrovascular disease were randomized into two groups. Patients in the first group (n=60) were treated with vinpocetine 30 mg daily and vestibular rehabilitation exercises, while patients in the second group (n=60) performed only vestibular rehabilitation exercises. The effectiveness of treatment was evaluated using clinical scales (VAS-V, DHI, DAI). BDNF plasma levels were measured before and after treatment.
Vinpocetine reduced the severity of dizziness, improved physical activity and attitude to treatment and increased the expression of BDNF.
Vinpocetine can be used for treatment of the diseases that require stimulation of neuroplasticity.
Cerebrovascular disease, dizziness, neuroplasticity, BDNF, vinpocetine.